Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares Issued
Growth Metrics
Income Statement
Others
Ratios

TriSalus Life Sciences (TLSIW) Change in Receivables (2022 - 2026)

TriSalus Life Sciences posted quarterly Change in Receivables of -$1.3 million for Q1 2026, down 452.73% year-on-year from $366000.0 in Q1 2025, and down 181.14% on a QoQ basis from $1.6 million in Q4 2025.

TriSalus Life Sciences (TLSIW) has 5 years of Change in Receivables data on file, last reported at -$1.3 million in Q1 2026.

  • For the quarter ending Q1 2026, Change in Receivables fell 452.73% year-over-year to -$1.3 million; the trailing twelve-month figure through Mar 2026 stood at -$23000.0 (down 101.69% YoY), and the FY2025 full-year result was $1.6 million, down 4.94% from the prior year.
  • Change in Receivables for Q1 2026 stood at -$1.3 million, down from $1.6 million in the prior quarter.
  • Across five years, Change in Receivables topped out at $1.6 million in Q4 2025 and bottomed at -$1.3 million in Q1 2026.
  • The 5-year median for Change in Receivables is $363500.0 (2024), against an average of $236071.4.
  • The widest annual swing landed in 2024, when Change in Receivables surged 1965.71%; it then plunged 452.73% in 2026.
  • A 5-year view of Change in Receivables shows it stood at -$736000.0 in 2022, then jumped by 168.21% to $502000.0 in 2023, then fell by 28.09% to $361000.0 in 2024, then surged by 340.72% to $1.6 million in 2025, then slumped by 181.14% to -$1.3 million in 2026.
  • The last three Change in Receivables figures came in at -$1.3 million (Q1 2026), $1.6 million (Q4 2025), and -$497000.0 (Q3 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Change in Receivables (Qtr)
1 Abbott Laboratories 152.82 Bn 146.17 Bn 6.27 Bn 42.00 Mn
2 Stryker 115.07 Bn 112.19 Bn 3.81 Bn -444.00 Mn
3 Medtronic 95.25 Bn 87.08 Bn 5.76 Bn -13.00 Mn
4 Boston Scientific 71.38 Bn 70.17 Bn 3.61 Bn 117.00 Mn
5 Edwards Lifesciences 51.08 Bn 47.41 Bn 1.29 Bn 117.90 Mn
6 Koninklijke Philips 29.38 Bn 26.07 Bn 2.07 Bn -
7 Dexcom 28.84 Bn 27.72 Bn 750.30 Mn -124.60 Mn
8 GE HealthCare Technologies 28.56 Bn 26.49 Bn 1.98 Bn -141.00 Mn
9 Steris 20.71 Bn 20.30 Bn 697.10 Mn 123.50 Mn
10 TriSalus Life Sciences - - 7.67 Mn -1.29 Mn

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 -1.29 Mn
Mar 31, 2026 -1.29 Mn
Dec 31, 2025 1.59 Mn
Dec 31, 2025 1.59 Mn
Sep 30, 2025 -497,000.00
Sep 30, 2025 -497,000.00
Jun 30, 2025 174,000.00
Jun 30, 2025 174,000.00
Mar 31, 2025 366,000.00
Mar 31, 2025 366,000.00
Dec 31, 2024 361,000.00
Dec 31, 2024 361,000.00
Sep 30, 2024 206,000.00
Sep 30, 2024 206,000.00
Jun 30, 2024 429,000.00
Jun 30, 2024 429,000.00
Mar 31, 2024 723,000.00
Mar 31, 2024 723,000.00
Dec 31, 2023 502,000.00
Dec 31, 2023 502,000.00
Sep 30, 2023 940,000.00
Sep 30, 2023 940,000.00
Jun 30, 2023 502,000.00
Jun 30, 2023 502,000.00
Mar 31, 2023 35,000.00
Mar 31, 2023 35,000.00
Dec 31, 2022 -736,000.00
Dec 31, 2022 -736,000.00